CompletedNCT00327834
Atomoxetine or placebo for binge eating
About this title
Atomoxetine in the Treatment of Binge Eating Disorder
Read the official source — NCT00327834Medication studyAges 18–65United StatesEating disorders
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- CincinnatiSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateMay 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Lindner Center of HOPE
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00327834
- Official title
Show the full official title
Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cincinnati
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Lindner Center of HOPE.
Did this study involve medication?
Yes. The study involved medication, including atomoxetine.
Who was this study for?
Listed age limits: 18 years to 65 years.
